• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Dr. Shore discusses effects of darolutamide on urinary and bowel symptoms


“We [found] that patients' overall [total] bowel symptoms scores were improved for those of the patients who received the active therapeutic treatment of [darolutamide] versus placebo,” says Neal D. Shore, MD, FACS.

In this video, Neal D. Shore, MD, FACS, discusses the background and findings of the study, “Impact of darolutamide on local symptoms in patients with nonmetastatic castration-resistant prostate cancer,” presented recently at the 2021 American Urological Association annual meeting. Shore is the director of the Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, South Carolina.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.